1-3 of 3
April Cox
Close
Sort by
Journal Articles

Combination of the KSP Inhibitor ARRY-520 with Bortezomib or Revlimid Causes Sustained Tumor Regressions and Significantly Increased Time to Regrowth in Models of Multiple Myeloma.

Richard Woessner, Brian Tunquist, April Cox, Sumeet Rana, Duncan Walker, Patrice A. Lee
Journal: Blood
Blood (2009) 114 (22): 2858.
https://doi.org/10.1182/blood.V114.22.2858.2858
Published: 2009
Journal Articles

Characterization of the Effects of Pim Kinase Inhibition on Multiple Oncogene-Driven Cell Lines

Stefan David Gross, PhD, John E Robinson, Shelley Allen, April Cox, Walt E DeWolf, Sarah Galbraith, Patrice Lee, Christine Lemieux, Joseph P Lyssikatos, Fredrik Marmsater, Matthew Martinson, Mark C Munson, Ross D Wallace, Rich Woessner, John Zuzack, James Winkler, PhD, Kevin Koch
Journal: Blood
Blood (2008) 112 (11): 2662.
https://doi.org/10.1182/blood.V112.11.2662.2662
Published: 2008
Journal Articles

ARRY-429520, a KSP Inhibitor with Efficacy in Animal Models of Solid and Liquid Tumors.

Rich Woessner, PhD, Chris Corrette, Ph.D., Shelley Allen, Ph.D., Jeremy Hans, Ph.D., Qian Zhao, Ph.D., Tom Aicher, Ph.D., Joe Lyssikatos, Ph.D., John Robinson, Ph.D., Greg Poch, Ph.D., Laura Hayter, A.S., April Cox, M.S., Patrice Lee, Ph.D., James Winkler, Ph.D., Kevin Koch, Ph.D., Eli Wallace, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 4388.
https://doi.org/10.1182/blood.V108.11.4388.4388
Published: 2006